JP Morgan Chase’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-200
| Closed | -$7K | – | 7442 |
|
|
2023
Q1 | $7K | Sell |
200
-297,300
| -100% | -$13.4M | ﹤0.01% | 6197 |
|
|
2022
Q4 | $13.5M | Buy |
297,500
+275,600
| +1,258% | +$17.8M | ﹤0.01% | 1995 |
|
|
2022
Q3 | $1.53M | Sell |
21,900
-111,900
| -84% | -$8.28M | ﹤0.01% | 3681 |
|
|
2022
Q2 | $8.98M | Buy |
133,800
+17,000
| +15% | +$1.08M | ﹤0.01% | 2255 |
|
|
2022
Q1 | $9.6M | Buy |
116,800
+102,200
| +700% | +$10.5M | ﹤0.01% | 2414 |
|
|
2021
Q4 | $2.14M | Sell |
14,600
-8,400
| -37% | -$1.3M | ﹤0.01% | 3808 |
|
|
2021
Q3 | $4.07M | Buy |
23,000
+10,300
| +81% | +$1.66M | ﹤0.01% | 3204 |
|
|
2021
Q2 | $2.05M | Buy |
+12,700
| New | +$2.04M | ﹤0.01% | 3778 |
|
|
2020
Q4 | – | Sell |
-93,500
| Closed | -$15.5M | – | 6025 |
|
|
2020
Q3 | $15.5M | Buy |
93,500
+61,500
| +192% | +$8.42M | ﹤0.01% | 1679 |
|
|
2020
Q2 | $3.65M | Sell |
32,000
-90,000
| -74% | -$8.73M | ﹤0.01% | 2696 |
|
|
2020
Q1 | $9.38M | Buy |
122,000
+87,000
| +249% | +$7.8M | ﹤0.01% | 1800 |
|
|
2019
Q4 | $4.51M | Buy |
+35,000
| New | +$3.38M | ﹤0.01% | 2768 |
|
|
2019
Q3 | – | Sell |
-50,000
| Closed | -$5.24M | – | 6024 |
|
|
2019
Q2 | $5.24M | Buy |
50,000
+24,000
| +92% | +$1.87M | ﹤0.01% | 2602 |
|
|
2019
Q1 | $1.91M | Buy |
+26,000
| New | +$1.77M | ﹤0.01% | 3361 |
|
|
2018
Q3 | – | Sell |
-27,000
| Closed | -$1.33M | – | 5883 |
|
|
2018
Q2 | $1.33M | Buy |
+27,000
| New | +$1.02M | ﹤0.01% | 3665 |
|
Other funds holding MRTX
JP Morgan Chase's MRTX Position: Q1 2024 in Review
JP Morgan Chase sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 108,407 shares — an estimated $6.37M sold.
JP Morgan Chase first reported a position in MRTX in Q3 2014 and held it in 35 quarters. The position peaked at $78.9M in Q4 2020. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.
- JP Morgan Chase reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
- JP Morgan Chase sold 108,407 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $6.37M.
- JP Morgan Chase first reported a position in Mirati Therapeutics, Inc. Common Stock in Q3 2014 and held it in 35 quarters.
- JP Morgan Chase's Mirati Therapeutics, Inc. Common Stock position peaked at $78.9M in Q4 2020.
- 2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.
Based on JP Morgan Chase's 13F filing for Q1 2024, filed 10 May 2024.